Pharmacotherapy Home

Pharmacotherapy

Faculty

Photo

Talbert, Robert L., Pharm.D.
SmithKline Centennial Professor
of Pharmacotherapy
210- 567-8318
talbert@uthscsa.edu


Publications

Talbert RL. Lipid management by pharmacists: evidence of benefits. Journal of the American Pharmaceutical Association. 2000;40:143-4.

Talbert RL, Nappi JM. Combination antiplatelet therapy. U.S. Pharmacist 2000;25:86-98.

Crawford KM, Talbert RL. Antiplatelet therapy in secondary stroke prevention. Expert Opinion in Pharmacotherapy 2001;2;1609-1613.

Talbert RL. Management of lipid disorders in the 21st century. Texas Pharmacy Fall 2001:9-12.

Stringer KM, Lopez L, Talbert RL. A Call for Pharmacists to Improve the Care of Myocardial Infarction Patients. Pharmacotherapy 2001;21:1317-1319.

CTAP Consensus Panel Report and Scientific Roundtable. Acute Myocardial Infarction and Ischemic Coronary Syndromes: Optimizing Selection of Reperfusion and Revascularization Therapies in the Coronary Care Unit and Emergency Department. Hospital Pharmacists Consensus Reports. 2001; December:1-24.

Nathisuwan S, Talbert RL. A review on vasopeptidase inhibitors: a new modality in the treatment of hypertension and congestive heart failure. Pharmacotherapy 2002;22:27-42.

Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. Journal of Medical Microbiology. 2002:51:105-109.

Hawkins DW, Bradberry JC, Cziraky M, Talbert RL, Bartels D, Cerdeny J. NPCC Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward Better Patient Outcomes and New Roles for Pharmacists. Pharmacotherapy 2002;22:436-444.

Nappi JM, Talbert RL. Rationale for dual oral antiplatelet therapy to prevent recurrent ischemic events. American Journal of Health-System Pharmacists 2002:59:1723-1735.

Koeller JM, Talbert RL. Modification of HDL-Cholesterol in the Management of Cardiovascular Risk. Pharmacotherapy 2002;22:1266-1277.

Talbert RL, Spinler SA, Nappi JM, Bottorff M. Combination antiplatelet therapy: Implications for pharmacists. Pharmacotherapy 2002:22:1211-1215.

Talbert RL. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III. American Journal of Managed Care 2002;8(suppl.):S301-S307.

Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Annals of Internal Medicine 2003;138:831-838.

Hart RG, Leonard AD, Talbert, Rl, Pearce LA, Cornell E, Bovill E,, Feinberg WM. Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease. Pharmacotherapy 2003;23:579-584.

Recio V, Talbert RL. Low HDL-Cholesterol and the Risk of Heart Disease in Men. Texas Pharmacy Spring 2003, p. 22-25.

Frei CR, Koeller, JM, Burgess, DS, Talbert, RL, Johnsrud, MT . Impact of Antimicrobial Therapy on Outcomes in Hospitalized Patients with Community-Acquired Pneumonia. Pharmacotherapy 2003;23:1167-1174.

Talbert RL. Niacin in the Treatment of Dyslipidemia: Insight from ATP III. Introduction. American Journal of Health-System Pharmacy 2003;60 (supplement ):S1-S2.

Talbert RL. Role of the National Cholesterol Education Program Adult Treatment Panel III Guidelines in Managing Dyslipidemia. American Journal of Health-System Pharmacy 2003;60 (supplement ):S3-S8.

Talbert RL Pieper JA, Ito MK. Niacin and the NCEP ATP III Guidelines: Case Studies. American Journal of Health-System Pharmacy 2003;60 (supplement):S22-S24.

V. Mahaguna, R. L. Talbert, J. I. Peters, S. Adams, T. D. Reynolds, F. Y. W. Lam, and R. O. Williams III, Influence of Hydroxypropyl Methycellulose Polymer on In Vitro and In Vivo Performance of Controlled Release Tablets Containing Alprazolam, European Journal of Pharmaceutics and Biopharmaceutics 2003;56:461-468.

Feldman AM, Giles TD, Pina IL, Talbert RL. Clinical Trials of Beta Blockers for Heart Failure: Questions and Controversies. Cardiology Review November 2003.

Talbert RL. Current Recommendations for the Treatment of Dyslipidemia. Pharmacy and Therapeutics 2004;29:104-112.

Bauman JL, Talbert RL. Pharmacodynamics of Beta-Blockers in Heart Failure: Lessons from the Carvedilol or Metoprolol European Trial. Journal of Cardiovascular Pharmacology and Therapeutics 2004;9:1-12.

Bristow MR, Adams KF Jr., Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. Roundtable Discussion. The COMET Trial. Congestive Heart Failure 2005;11(1):39-47.

McKenney JM, Bradberry JC, Talbert RL, Cahill E, Brown VW. A national survey of pharmacists about coronary heart disease, high blood cholesterol, OTC statin therapy and pharmacists’ services. Journal of the American Pharmacists Association. 2004;44:562-568.

Talbert RL. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Failure Reviews 2004;9:131-137.

McConville JT, Carvalho TC, Iberg AN, Talbert RL, Burgess DS, Peters JI, Johnston KP, Williams III RO. Design and Evaluation of a Restraint-Free Small Animal Inhalation Dosing Chamber, Drug Development and Industrial Pharmacy, 1(2005) 35-42.

McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Hoeben BJ, Frei BL, Burgess DS, Talbert RL, Peters JI, Johnston KP, Williams III RO. Novel Treatment using Itraconazole Delivered via the Pulmonary Route and Enhanced Survival Following Invasive Pulmonary Aspergillosis in the Murine Model – Submitted to legal for intellectual property clearance.

Martin C, Talbert RL. Aspirin resistance. An evaluation of current evidence and measurement methods. Pharmacotherapy 2005;25:942-953.


Books
Pharmacotherapy: A Pathophysiologic Approach, 6th Edition, DiPiro JT, Talbert RL,, Yee GC, Matzke GR, Wells BG and Posey LM (eds), McGraw-Hill Publishing, Inc., New York, NY. 2005. (Section Editor - Cardiovascular Disorders pp. 149-494, Respiratory Disorders pp. 495-604, Endocrine Disorders pp. 1333-1424.


Book Chapters
Talbert RL, Bertin RJ. Chapter 120. Specialization in Pharmacy. In Remington: The Science and Practice of Pharmacy, 21st Edition, Popovich, N (eds), Advanced Concepts Institute, University of the Sciences in Philadelphia, Philadelphia, PA. 2005, pp. 2155–2162 .

Talbert RL. Cardiovascular Testing. In Pharmacotherapy: A Pathophysiologic Approach, 6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM (eds), McGraw-Hill Publishing, Inc., New York, NY. 2005, pp. 149-190.

Talbert RL. Thyroid Disorders. In Pharmacotherapy: A Pathophysiologic Approach, 6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM (eds), McGraw-Hill Publishing, Inc., New York, NY. 2005, pp. .1369-1390.

Talbert RL. Ischemic Heart Disease. In Pharmacotherapy: A Pathophysiologic Approach, 4th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM (eds), McGraw-Hill Publishing, Inc., New York, NY. 2005. pp. 261-290.

Talbert RL. Hyperlipidemia. In Pharmacotherapy: A Pathophysiologic Approach, 6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM (eds), McGraw-Hill Publishing, Inc., New York, NY. 2005, pp. 429-454.

Hoeben BJ, Talbert RL. Peripheral Vascular Disease. In Pharmacotherapy: A Pathophysiologic Approach, 6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM (eds), McGraw-Hill Publishing, Inc., 2005, pp. 453-460.


Abstracts
Nash JD, Burgess DS, Talbert RL. Effect of HMG CoA reductase inhibitors on fluconazole activity against Candida albicans. Pharmacotherapy 2000;20:370.

Pace IP, Talbert RL, Trice S. Cost-efficacy analysis of influenza vaccination versus neuriaminidase inhibitors. International Pharmaceutical Abstracts 2000;37:810.

Talbert RL. Evolution of thrombolytic therapy from infusion to bolus and combination with IIb/IIIa receptor antagonists. International Pharmaceutical Abstracts 2000;37:801.

Raehl CL, Talbert RL, Bottorff M, MacLaughlin EJ. Heart Failure Care: Room for a Pharmacist. ASHP Midyear Clinical Meeting. 2000;35(Dec):p PI-5.

Talbert RL, Raehl CL, Bottorff MD, MacLaughlin EJ. Heart failure care and background therapy. ASHP Midyear Clinical Meeting. 35(Dec):pPI-5, 2000.

Talbert RL. Evolution of thrombolytic therapy from infusion to bolus and combination with IIb/IIIa recetpro antagonists. ASHP Annual Meeting. 57(Jun):pPI-58, 2000.

Williams RO, Mahaguna V, Lam YWF, Peters JI, Adams S, Reynolds TD, Talbert RL. Formulation development and pharmacokinetic study of alprazolam contained in HPMC controlled release tablets. Pharmaceutical Research 2001; (accepted).

Talbert RL, Mahaguna V, Peters JI, Adams S, Reynolds TD, Williams RO III, Lam YWF. Pharmacodynamics of alprazolam formulated in HPMC controlled release tablets. Pharmaceutical Research 2001; (accepted).

Nathisuwan S, Talbert RL. Adherence to acute myocardial infarction treatment guidelines and clinical outcomes. Pharmacotherapy 2001;21:1260.

Frei BL, Frei CR, Talbert RL. Evaluation of Perioperative b-Blocker Use for the Prevention of Cardiovascular Complications in Elective, Noncardiac Surgery. Pharmacotherapy 2002;22:1328.

Frei BL, Frie CL, Talbert RL. Evaluation of ACE inhibitiors for the prevention of cardiovascular complications and death after elective, noncardiac surgery. Pharmacotherapy 2003;23:393-394.

Benavente O, Hart R, Palacio S, Pearce L, Roldon A, Talbert R, Bazan C, Shepherd A. Secondary Prevention of Small Subcortical Stroke (SPS3) Pilot Trial: Final Results. Stroke (submitted).

Shepherd, AMM, Roldan A, Palacio S, Benavente O, Hart R, Williams L, Holliday, S Talbert, RL, Roman G, Sherman D, Pearce L. Blood pressure results from the SPS3 pilot study. American Journal of Hypertension (submitted).

Lopez TC, Rascati KL, Young VS, Knodel LC, Talbert RL. Incidence of antidiabetic medication use following atypical antipsychotic use in a Texas Medicaid population. Pharmacotherapy 2003;23:#244.

McConville JT, Overhoff KA, Prapasri S, Hoeben BJ, Frei BL, Burgess DS, Talbert RL, Peters JI, Johnston KP, Williams RO III. Delivery of Poorly Water Soluble Drugs using Nebulization, Proceedings of the 15th Drug Delivery to the Lung Conference, London, United Kingdom, 2004.

Hoeben BJ, Burgess DS, Najvar LK, Talbert RL, McConville JT, Peters JI, Graybill JR, Jones, BL, Wiederhold NP, Williams RO. In vivo efficancy of aerosolized nanostructure itraconazole (ITR) formuations for the prevention of invasive pulmonary aspergillosis (IPA). ICAAC (submitted)

Hoeben BJ, D.S. Burgess DS, Najvar LK, Talbert RL, McConville JT, .Peters JI, , R. Bocanegra R, Graybill JR, ,Jones BL, Wiederhold NP, Williams RO III.. In vivo Efficacy of Aerosolized Nano-structured Itraconazole (ITZ) Formulations for the Prevention of Invasive Pulmonary Aspergillosis (IPA) ICAAC (submitted)


More information about Dr. Talbert
> Return to Dr. Talbert's Home Page

Last Reviewed: June 4, 2008

Division Information

Mailing Address:
Pharmacotherapy
Education & Research Ctr.
College of Pharmacy
The University of Texas
Health Science Center
7703 Floyd Curl Drive - MC 6220
San Antonio, TX
78229-3900
USA

Email Address: pharmacy
@austin.utexas.edu

Phone:
1-210-567-8355


Reveles Traces Rate of Hospital Infections

Dr. Kelly Reveles, assistant professor of pharmacotherapy, is primary author of a study which found that the incidence of Clostridium difficile infection (CDI), a highly contagious gastrointestinal disease often linked to the overprescribing of antibiotics, nearly doubled between 2001 and 2010. It also determined there were no improvements in patient health outcomes, including mortality or hospital length of stay, over the study period.

Read more about Reveles' study.

index of the major headings: a b c d e f g h i j k l m n o p q r s t u v w x y z